- Fungal & Yeast
- Other microbes
Microbial Biopharmaceuticals Market size was valued at USD 308 billion in 2022 and is poised to grow at a significant CAGR of 14.7% over 2023-2029. The microbial biopharmaceuticals market Increase in the geriatric population and changes in lifestyles are increasing the demand for biopharmaceuticals. An increase in research facilities and more approved biopharmaceutical products in the market are also key factors affecting the market. Frequent cases of side effects and incompatibilities in cases of mammalian or plant-obtained biopharmaceutical products cause the rise in demand for microbial products as they do not possess any side effects. They can be manufactured easily at low cost and are more stable in atmospheric and biological conditions. Microbes have been used to make bread, wine, vinegar, and other common items for millennia, with no one knowing the scientific basis. Nonmicrobial goods such as insulin, interferon, human growth hormone, and viral vaccinations are now commercially produced using genetically altered organisms. Microbes are also employed to produce energy (biodiesel and bioethanol), as well as to clean up contaminants like sewage and oil spills. Microorganisms contribute to increased agricultural production as active ingredients in biofertilizers and biopesticides, and microbes are the foundation of cost-effective mining and metallurgical technologies. The global microbial biopharmaceuticals market is surging owing to frequent acquisitions and launches by the market players.
Microbial Biopharmaceuticals Market Key Development:
In 2013, Sanofi a French pharmaceutical company announced that a strain of baker's yeast capable of producing malaria drugs on an industrial scale had successfully engineered by their researchers and it is commercially available now.
Fastest Growing Market
Microbial biopharmaceuticals are simply defined as the biopharmaceutical products which are extracted from microbial species by using recombinant DNA technology. These products have various benefits when compared to other biopharmaceutical products such as easy manufacture and extraction, low of cost, more stability, high potency, no or very less side effects and high therapeutic nature etc. thus, the market for these microbial biopharmaceuticals are showing significant growth.
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.